Table 2.

Associations between c-MYC amplification or polysomy for chromosome 8 and progression-free survival or overall survival.

	Progression-free survivala						Overall survivala
	Unadjusted model			Adjusted modelb			Unadjusted model			Adjusted modelb
	HR	95% CI	p-value	HR	95% CI	p-value	HR	95% CI	p-value	HR	95% CI	p-value
c-MYC amplificationc
≥ 2 c-MYC/CEP8 copies
No	1.00			1.00			1.00			1.00
Yes	1.03	0.65–1.64	0.884	1.03	0.57–1.85	0.922	1.08	0.68–1.72	0.745	1.01	0.56–1.80	0.982
c-MYC amplificationd
≥ 1.5 c-MYC/CEP8 copies
No	1.00			1.00			1.00			1.00
Yes	1.37	0.89–2.10	0.151	1.06	0.63–1.77	0.837	1.14	0.74–1.76	0.555	1.03	0.60–1.75	0.920
Polysomy for chromosome 8e
≥ 4 CEP8 copies
No	1.00			1.00			1.00			1.00
Yes	0.99	0.62–1.59	0.982	1.07	0.57–2.02	0.823	1.08	0.67–1.74	0.747	1.04	0.54–1.99	0.916

Estimated hazard ratio (HR), 95% confidence interval (95% CI).

^aCox regression analysis for modeling the relative risk of disease progression or death; p-values are based on the Wald test.

^bModels were adjusted for patient age at enrollment in years, and stratified by tumor stage (III vs. IV), histologic subtype (clear cell or mucinous vs. other histologic subtypes), tumor grade (well differentiated vs. moderately differentiated vs. poorly differentiated), measurable disease status (non-measurable vs. measurable), and treatment regimen (cyclophosphamide + cisplatin vs. paclitaxel + cisplatin).

^cc-MYC amplification was categorized as ‘No’ when tumors had <2 copies of c-MYC/CEP8 per cell or ‘Yes’ when tumors had ≥2 copies of c-MYC/CEP8 per cell.

^dc-MYC amplification was categorized as ‘No’ when tumors had <1.5 copies of c-MYC/CEP8 per cell or ‘Yes’ when tumors had ≥1.5 copies of c-MYC/CEP8 per cell.

^ePolysomy for chromosome 8 was categorized as ‘No’ when tumors had <4 copies of CEP8 per cell or ‘Yes’ when tumors had ≥4 copies of CEP8 per cell.